s

¿ A story on autoimmune diseases in the Aug. 2, 2001, issue of BioWorld Today misidentified the position of David Lo, who authored a ¿Perspective¿ piece on T-cell activation in the Science article that was the subject of the BioWorld story. Lo is vice president, integrative biology, at Digital Gene Technologies Inc. in La Jolla, Calif.

¿ A news item on Stressgen Biotechnologies Corp. in the Aug. 2, 2001, issue of BioWorld Today mistakenly said the company completed enrollment in a Phase II trial of HspE7 for anal dysplasia caused by HPV. It actually completed Phase III enrollment.

Editor¿s Note: The corrections have been made in BioWorld Online.

No Comments